3 completed, 3 terminated, 3 unknown, 2 active not recruiting. 7 Phase 1, 5 Phase 2, 4 Phase 3, 2 Phase 4.
Follow Diluent: new trials by email Literature Review of Diluent trials Research Report on Diluent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa. mRNA-1645-eODGT8, mRNA-1645-CoreG28v2, mRNA-1645-N332GT5 - HIV Infections | Phase 1 | Active not recruiting | International AIDS Vaccine Initiative | 96 | 2025-12-15 | 2026-07-01 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health 426c.Mod.Core-C4b, HxB2.WT.Core-C4b, 3M-052-AF adjuvant - HIV | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 42 | 2025-03-17 | 2025-09-25 |
| A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration SAR402663, Diluent - Neovascular Age-related Macular Degeneration | Phase 1 / Phase 2 | Active not recruiting | Sanofi | 66 | 2024-11-21 | 2026-07-16 |
| First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) ALN-SOD, Diluent, Placebo (PB) - Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 54 | 2024-08-28 | 2026-09-11 |
| Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens TNX-2110, TNX-2120, TNX-2130 - Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2 | Phase 1 | Terminated | Tonix Pharmaceuticals, Inc. | 9 | 2022-01-07 | 2024-11-06 |
| Brain Insulin Resistance in Mood Disorders Humulin R, Diluent - Major Depressive Disorder, Bipolar Disorder | Phase 1 / Phase 2 | Unknown | University Health Network, Toronto | 150 | 2021-10-06 | 2023-12-15 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee Resiniferatoxin, Placebo - Osteoarthritis, Knee, Knee Pain Chronic | Phase 3 | Withdrawn | Sorrento Therapeutics, Inc. | 2020-12-01 | 2021-11-09 | |
| suPAR to Guide Antibiotics in Emergency Department Meropenem, Placebo - Sepsis | Phase 2 / Phase 3 | Unknown | Hellenic Institute for the Study of Sepsis | 220 | 2018-10-27 | 2020-07-30 |
| Testing if BCG (Bacille Calmette-Guérin) Vaccination Can Induce Innate Immune Training in Adult People Above 50 Years of Age in Guinea-Bissau Bacille Calmette-Guerin, BCG solvent - Innate Immunity, Bacille Calmette-Guérin | Phase 4 | Completed | Bandim Health Project | 40 | 2017-02-01 | 2021-04-26 |
| Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls Capsaicin, diluent - Rhinitis | Phase 4 | Completed | Universitaire Ziekenhuizen KU Leuven | 39 | 2012-02-01 | 2014-12-05 |
| Sildenofil in Persistent Pulmonary Hypertension in Newborns Sildenafil, diluent - Persistent Fetal Circulation Syndrome | Phase 3 | Unknown | Hamad Medical Corporation | 100 | 2011-11-01 | 2012-09-25 |
| Recombinant Human Relaxin for the Treatment of Decompensated CHF Placebo, Recombinant human relaxin (rhRlx) - Congestive Heart Failure (CHF) | Phase 2 | Terminated | Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies | 11 | 2006-11-01 | 2014-05-07 |
| Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge House Dust Mite, Diluent - Atopic Asthma, Healthy | Phase 1 | Terminated | John Sundy | 40 | 2006-10-01 | 2013-07-16 |
| The Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder Intranasal Insulin, Diluent - Bipolar Disorder | Phase 3 | Completed | University Health Network, Toronto | 60 | 2006-05-01 | 2009-07-13 |
Bipolar Disorder (2) · HIV Infections (2) · Amyotrophic Lateral Sclerosis (1) · Anhedonia (1) · Asthma (1) · Depressive Disorder, Major (1) · Heart Failure (1) · Hypersensitivity (1) · Osteoarthritis, Knee (1) · Persistent Fetal Circulation Syndrome (1) · Rhinitis (1) · Sepsis (1)
University Health Network, Toronto (2) · Bandim Health Project (1) · Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies (1) · Hamad Medical Corporation (1) · Hellenic Institute for the Study of Sepsis (1) · International AIDS Vaccine Initiative (1) · John Sundy (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Regeneron Pharmaceuticals (1) · Sanofi (1) · Sorrento Therapeutics, Inc. (1) · Tonix Pharmaceuticals, Inc. (1) · Universitaire Ziekenhuizen KU Leuven (1)
United States (4) · Canada (3) · Belgium (2) · Australia (1) · Germany (1) · Greece (1) · Guinea-Bissau (1) · Japan (1) · Poland (1) · Qatar (1) · Russia (1) · South Africa (1) · South Korea (1) · Sweden (1) · Taiwan (1)
Evangelos Giamarellos-Bourboulis, MD, PhD (1) · Herb Harris, MD (1) · Husam Salama, MD (1) · John S Sundy, M.D., PhD. (1) · Laura Van Gerven, Doctor (1) · Linda-Gail Bekker (1) · Monica Luchi, MD (1) · Peter Hellings, Doctor (1) · Roger McIntyre, MD, FRCPC (1) · Thomas Dschietzig, MD (1)
PMID 33534419, PMID 38321472, PMID 39423450
2023 (1)